{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:17:19Z","timestamp":1783430239648,"version":"3.54.6"},"reference-count":90,"publisher":"MDPI AG","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAPMA"],"published-print":{"date-parts":[[2006,1]]},"abstract":"<jats:p>Onychomycosis is a common problem. The desired outcome of treatment for patients and clinicians is complete cure (negative culture and negative potassium hydroxide examination results plus a completely normal nail). This cost analysis sought to determine the cost-effectiveness of treatments for onychomycosis using complete cure as a unit of effectiveness. A simplified cost-effectiveness analysis was conducted using complete cure rates from randomized, blinded clinical trials involving at least 50 participants. Trials were identified by searching the literature, manually searching for review articles, and reviewing medication package inserts. For each trial that met the entry criteria, three levels of cost were used to calculate medication cost per complete cure: commercial price, average wholesale price, and Veterans Affairs pharmacy price. In addition, a computerized economic model was used to determine total cost per complete cure, including all medical costs. The most cost-effective treatments were those that involved terbinafine: pulse, continuous, or in combination with other agents. Itraconazole, griseofulvin, and fluconazole were less cost-effective. Ciclopirox nail lacquer was at least three times more expensive than all other agents when evaluating total costs per complete cure. Overall, the lowest cost per complete cure resulted from terbinafine treatment, with most evidence supporting 3 months of continuous therapy. (J Am Podiatr Med Assoc 96(1): 38\u201352, 2006)<\/jats:p>","DOI":"10.7547\/0960038","type":"journal-article","created":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T10:15:49Z","timestamp":1396347349000},"page":"38-52","source":"Crossref","is-referenced-by-count":16,"title":["Evaluating Costs for Onychomycosis Treatments"],"prefix":"10.3390","volume":"96","author":[{"given":"Erin M.","family":"Warshaw","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Minnesota, Minneapolis; Veterans Affairs Medical Center, Minneapolis. Mailing address: Dept 111 K VAMC, Dermatology, 1 Veterans Dr, Minneapolis, MN 55417."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","reference":[{"key":"R1","series-title":"J Am Acad Dermatol","first-page":"641","volume":"43","year":"2000","unstructured":"Ghannoum MA, Hajjeh RA, Scher R, et al: A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis fungal distribution and antifungal susceptibility patterns. .J Am Acad Dermatol43::641. ,2000. .11004620"},{"key":"R2","series-title":"Vital Health Stat","first-page":"1","volume":"212","year":"1978","unstructured":"Johnson MT, Roberts J: Skin conditions and related need for medical care among persons 1\u201374 years, United States, 1971\u20131974. .Vital Health Stat212::1. ,1978. ."},{"key":"R3","series-title":"Br J Dermatol","first-page":"23","volume":"126","year":"1992","unstructured":"Roberts DT: Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. .Br J Dermatol126::23. ,1992. .1531924"},{"key":"R4","series-title":"Br J Dermatol","first-page":"67","volume":"91","year":"1974","unstructured":"English MP, Atkinson R: Onychomycosis in elderly chiropody patients. .Br J Dermatol91::67. ,1974. .4277596"},{"key":"R5","series-title":"Arch Dermatol","first-page":"1172","volume":"133","year":"1977","unstructured":"Elewski BE, Charif MA: Prevalence of onychomycosis in patients attending a dermatology clinic in Northeastern Ohio for other conditions. .Arch Dermatol133::1172. ,1977. ."},{"key":"R6","series-title":"Br J Dermatol","first-page":"32","volume":"130","year":"1994","unstructured":"Einarson TR, Arikian SR, Shear NH: Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective. .Br J Dermatol130: (suppl 43):32. ,1994. .8186140"},{"key":"R7","series-title":"Br J Dermatol","first-page":"35","volume":"130","year":"1994","unstructured":"Arikian SR, Einarson TR, Kobelt-Nguyen G, et al: A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. .Br J Dermatol130: (suppl 43):35. ,1994. .8186141"},{"key":"R8","series-title":"Clin Ther","first-page":"757","volume":"18","year":"1996","unstructured":"Marchetti A, Piech CT, McGhan WF, et al: Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model. .Clin Ther18::757. ,1996. .8879902"},{"key":"R9","series-title":"Pharmacoeconomics","first-page":"401","volume":"19","year":"2001","unstructured":"Jansen R, Redekop WK, Rutten FFH: Cost effectiveness of continuous terbinafine compared with intermittent itraconazole in the treatment of dermatophyte toenail onychomycosis. .Pharmacoeconomics19::401. ,2001. .11383756"},{"key":"R10","series-title":"Clin Ther","first-page":"559","volume":"19","year":"1997","unstructured":"Einarson TR: Pharmacoeconomic applications of meta-analysis for single groups using antifungal onychomycosis lacquers as an example. .Clin Ther19::559. ,1997. .9220219"},{"key":"R11","series-title":"Pharmacoeconomics","first-page":"243","volume":"13","year":"1998","unstructured":"Gupta AK: Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails: a US analysis. .Pharmacoeconomics13::243. ,1998. .10178650"},{"key":"R12","series-title":"Pharmacoeconomics","first-page":"983","volume":"19","year":"2001","unstructured":"Joish VN, Armstrong EP: Which antifungal agent for onychomycosis? a pharmacoeconomic analysis. .Pharmacoeconomics19::983. ,2001. .11735669"},{"key":"R13","series-title":"Pharmacoeconomics","first-page":"267","volume":"19","year":"2001","unstructured":"Stier DM, Henke C, Schein J, et al: Cost of treatment for onychomycosis: data from a 9-month observational study. .Pharmacoeconomics19::267. ,2001. .11303415"},{"key":"R14","series-title":"Pharmacoeconomics","first-page":"319","volume":"20","year":"2002","unstructured":"Salo H, Pekurinen M: Cost effectiveness of oral terbinafine (Lamisil) compared with oral fluconazole (Diflucan) in the treatment of patients with toenail onychomycosis. .Pharmacoeconomics20::319. ,2002. .11994041"},{"key":"R15","series-title":"JAPMA","first-page":"272","volume":"92","year":"2002","unstructured":"Gupta AK: Treatment of dermatophyte toenail onychomycosis in the United States: a pharmacoeconomic analysis. .JAPMA92::272. ,2002. ."},{"key":"R16","series-title":"J Am Acad Dermatol","first-page":"S69","volume":"38","year":"1998","unstructured":"Bootman JL: Cost-effectiveness of two new treatments for onychomycosis: an analysis of two comparative clinical trials. .J Am Acad Dermatol38::S69. ,1998. .9594941"},{"key":"R17","series-title":"J Am Acad Dermatol","first-page":"S81","volume":"43","year":"2000","unstructured":"Gupta AK: Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. .J Am Acad Dermatol43::S81. ,2000. .11051137"},{"key":"R18","series-title":"Br J Dermatol","first-page":"660","volume":"139","year":"1998","unstructured":"Humphrey KM, Cork MJ, Haycox A: A retrospective cost-effectiveness analysis of the treatment of onychomycosis in general practice. .Br J Dermatol139::660. ,1998. .9892910"},{"key":"R19","year":"2003","unstructured":"Omar MA, Kahler KH: Cost-effectiveness analysis of therapies for the treatment of toenail onychomycosis. Poster presented at the 61st annual meeting of the American Academy of Dermatology, March 21\u201326. ,2003. , San Francisco."},{"key":"R20","series-title":"J Am Acad Dermatol","first-page":"72","volume":"32","year":"1995","unstructured":"Haneke E, Tausch I, Brautigam M, et al: Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin: LAGOS III Study Group. .J Am Acad Dermatol32::72. ,1995. .7822520"},{"key":"R21","series-title":"J Am Acad Dermatol","first-page":"479","volume":"44","year":"2001","unstructured":"Gupta AK, Konnikov N, Lynde CW: Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. .J Am Acad Dermatol44::479. ,2001. .11209118"},{"key":"R22","series-title":"Arch Dermatol","first-page":"919","volume":"131","year":"1995","unstructured":"Hofmann H, Brautigam M, Weidinger G, et al: Treatment of toenail onychomycosis: a randomized, double-blind study with terbinafine and griseofulvin: LAGOS II Study Group. .Arch Dermatol131::919. ,1995. .7632064"},{"key":"R23","series-title":"J Am Acad Dermatol","first-page":"S77","volume":"38","year":"1998","unstructured":"Scher RK, Breneman D, Rich P, et al: Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. .J Am Acad Dermatol38:(pt 2):S77. ,1998. .9631989"},{"key":"R24","series-title":"Cutis","first-page":"217","volume":"59","year":"1997","unstructured":"Elewski BE, Scher RK, Aly R, et al: Double-blind, randomized comparison of itraconazole capsules vs. placebo in the treatment of toenail onychomycosis. .Cutis59::217. ,1997. .9104548"},{"key":"R25","series-title":"J Am Acad Dermatol","first-page":"110","volume":"35","year":"1996","unstructured":"Odom R, Daniel CR, Aly R: A double-blind, randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail. .J Am Acad Dermatol35::110. ,1996. .8682945"},{"key":"R26","series-title":"Br J Dermatol","first-page":"16","volume":"134","year":"1996","unstructured":"De Backer M, De Keyser P, De Vroey C, et al: A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg\/day vs. itraconazole 200 mg\/day: a double-blind comparative trial. .Br J Dermatol134: (suppl 46):16. ,1996. .8763462"},{"key":"R27","series-title":"Br J Dermatol","first-page":"18","volume":"134","year":"1996","unstructured":"Brautigam M, Nolting S, Schopf RE, et al: German randomized double-blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection. .Br J Dermatol134: (suppl 46):18. ,1996. .8763463"},{"key":"R28","series-title":"Br J Dermatol","first-page":"230","volume":"136","year":"1997","unstructured":"Havu V, Brandt H, Heikkila H, et al: A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toenail onychomycosis. .Br J Dermatol136::230. ,1997. .9068738"},{"key":"R29","series-title":"Arch Dermatol","first-page":"919","volume":"131","year":"1995","unstructured":"Hofmann H, Brautigam M, Weidinger G, et al: Treatment of toenail onychomycosis: a randomized, double-blind study with terbinafine and griseofulvin. .Arch Dermatol131::919. ,1995. .7632064"},{"key":"R30","series-title":"J Am Acad Dermatol","first-page":"740","volume":"37","year":"1997","unstructured":"Drake LA, Shear NH, Arlette JP, et al: Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. .J Am Acad Dermatol37:(pt 1):740. ,1997. .9366820"},{"key":"R31","series-title":"Br J Dermatol","first-page":"97","volume":"142","year":"2000","unstructured":"Havu V, Heikkila H, Kuokkanen K, et al: A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. .Br J Dermatol142::97. ,2000. .10651701"},{"key":"R32","series-title":"J Am Acad Dermatol","first-page":"750","volume":"32","year":"1995","unstructured":"Faergemann J, Anderson C, Hersle K, et al: Double- blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. .J Am Acad Dermatol32::750. ,1995. .7722020"},{"key":"R33","series-title":"Br J Dermatol","first-page":"250","volume":"146","year":"2002","unstructured":"Heikkila H, Stubb S: Long-term results in patients with onychomycosis treated with terbinafine or itraconazole. .Br J Dermatol146::250. ,2002. .11903235"},{"key":"R34","series-title":"J Am Acad Dermatol","first-page":"S57","volume":"38","year":"1998","unstructured":"De Backer M, De Vroey C, Lesaffre E, et al: Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg\/day versus itraconazole 200 mg\/day. .J Am Acad Dermatol38:(pt 3):S57. ,1998. .9594939"},{"key":"R35","series-title":"J Am Acad Dermatol","first-page":"S95","volume":"38","year":"1998","unstructured":"Ling MR, Swinyer LJ, Jarratt MT, et al: Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. .J Am Acad Dermatol38:(pt 2):S95. ,1998. .9631991"},{"key":"R36","series-title":"J Am Acad Dermatol","first-page":"S70","volume":"43","year":"2000","unstructured":"Gupta AK, Fleckman P, Baran R: Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. .J Am Acad Dermatol43:(suppl):S70. ,2000. .11051136"},{"key":"R37","series-title":"Arch Dermatol","first-page":"1551","volume":"134","year":"1998","unstructured":"Epstein E: How often does oral treatment of toenail onychomycosis produce a disease-free nail? an analysis of published data. .Arch Dermatol134::1551. ,1998. .9875192"},{"key":"R38","series-title":"Int J Dermatol","first-page":"312","volume":"42","year":"2003","unstructured":"Gupta AK, Ryder J, Summerbell RC: Comparison of efficacy criteria across onychomycosis trials: need for standardization. .Int J Dermatol42::312. ,2003. .12694503"},{"key":"R39","series-title":"Int J Dermatol","first-page":"67","volume":"36","year":"1997","unstructured":"Friedman-Birnbaum R, Cohen A, Shemer A, et al: Treatment of onychomycosis: a randomized, double-blind comparison study with topical bifonazoleurea ointment alone and in combination with short-duration oral griseofulvin. .Int J Dermatol36::67. ,1997. .9071624"},{"key":"R40","series-title":"Antimicrob Agents Chemother","first-page":"2064","volume":"37","year":"1993","unstructured":"Korting HC, Schafer-Korting M, Zienicke H, et al: Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. .Antimicrob Agents Chemother37::2064. ,1993. .8257124"},{"key":"R41","series-title":"Br J Dermatol","first-page":"254","volume":"146","year":"2002","unstructured":"Farkas B, Paul C, Dobozy A, et al: Terbinafine (Lamisil) treatment of toenail onychomycosis in patients with insulin-dependent and non-insulin-dependent diabetes mellitus: a multicentre trial. .Br J Dermatol146::254. ,2002. .11903236"},{"key":"R42","series-title":"J Am Acad Dermatol","first-page":"775","volume":"33","year":"1995","unstructured":"Watson A, Marley J, Ellis D, et al: Terbinafine in onychomycosis of the toenail: a novel treatment protocol. .J Am Acad Dermatol33:(pt 1):775. ,1995. .7593777"},{"key":"R43","series-title":"J Dermatol","first-page":"648","volume":"25","year":"1998","unstructured":"Syed TA, Ahmadpour OA, Ahmad SA, et al: Management of toenail onychomycosis with 2% butenafine and 20% urea cream: a placebo-controlled, double-blind study. .J Dermatol25::648. ,1998. .9830263"},{"key":"R44","series-title":"Australas J Dermatol","first-page":"29","volume":"39","year":"1998","unstructured":"Watson AB, Marley JE, Ellis DH, et al: Long-term follow up of patients with toenail onychomycosis after treatment with terbinafine. .Australas J Dermatol39::29. ,1998. .9529685"},{"key":"R45","series-title":"BMJ","first-page":"1151","volume":"304","year":"1992","unstructured":"Goodfield MJ, Andrew L, Evans EG: Short term treatment of dermatophyte onychomycosis with terbinafine. .BMJ304::1151. ,1992. .1392793"},{"key":"R46","series-title":"Dermatology","first-page":"323","volume":"196","year":"1998","unstructured":"Haneke E, Tajerbashi M, De Doncker P, et al: Itraconazole in the treatment of onychomycosis: a double-blind comparison with miconazole. .Dermatology196::323. ,1998. .9621140"},{"key":"R47","series-title":"Dermatology","first-page":"40","volume":"194","year":"1997","unstructured":"Ellis DH, Marley JE, Watson AB, et al: Significance of non-dermatophyte moulds and yeasts in onychomycosis. .Dermatology194: (suppl 1):40. ,1997. .9154401"},{"key":"R48","series-title":"Br J Dermatol","first-page":"737","volume":"136","year":"1997","unstructured":"Tausch I, Brautigam M, Weidinger G, et al: Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double-blind trial comparing 6 and 12 weeks therapy: the Lagos V Study Group. .Br J Dermatol136::737. ,1997. .9205509"},{"key":"R49","series-title":"J Fam Pract","first-page":"601","volume":"38","year":"1994","unstructured":"Buck DS, Nidorf DM, Addino JG: Comparison of two topical preparations for the treatment of onychomycosis: Melaleuca alternifolia (tea tree) oil and clotrimazole. .J Fam Pract38::601. ,1994. .8195735"},{"key":"R50","series-title":"Br J Dermatol","first-page":"1177","volume":"142","year":"2000","unstructured":"Baran R, Feuilhade M, Combernale P, et al: A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region. .Br J Dermatol142::1177. ,2000. .10848743"},{"key":"R51","series-title":"J Dermatol Treat","first-page":"33","volume":"11","year":"2000","unstructured":"Gupta AK, Maddin S, Arlette J, et al: Itraconazole pulse therapy is effective in dermatophyte onychomycosis of the toenail: a double-blind placebo-controlled study. .J Dermatol Treat11::33. ,2000. ."},{"key":"R52","series-title":"Eur J Dermatol","first-page":"7","volume":"6","year":"1996","unstructured":"Haneke E, Delescluse J, Plinck EPB, et al: The use of itraconazole in onychomycosis. .Eur J Dermatol6::7. ,1996. ."},{"key":"R53","series-title":"J Eur Acad Dermatol Venerol","first-page":"215","volume":"9","year":"1997","unstructured":"Honeyman JF, Talarico FS, Arruda LHF, et al: Itraconazole versus terbinafine: which is better for the treatment of onychomycosis?. J Eur Acad Dermatol Venerol9::215. ,1997. ."},{"key":"R54","series-title":"Mycoses","first-page":"235","volume":"4","year":"1998","unstructured":"Ginter G, De Doncker P: An intermittent itraconazole 1-week dosing regimen for the treatment of toenail onychomycosis in dermatological practice. .Mycoses4::235. ,1998. ."},{"key":"R55","series-title":"Int J Dermatol","first-page":"70","volume":"36","year":"1997","unstructured":"Bonifaz A, Carrasco-Gerard E, Saul A: Itraconazole in onychomycosis: intermittent dose schedule. .Int J Dermatol36::70. ,1997. .9071625"},{"key":"R56","series-title":"Curr Ther Res","first-page":"481","volume":"58","year":"1997","unstructured":"Fraki JE, Heikkila HT, Kero MO, et al: An open-label noncomparative, multicenter evaluation of fluconazole with or without urea nail pedicure for treatment of onychomycosis. .Curr Ther Res58::481. ,1997. ."},{"key":"R57","series-title":"Int J Dermatol","first-page":"587","volume":"35","year":"1996","unstructured":"Montero-Gei F, Robles-Soto ME, Schlager H: Fluconazole in the treatment of severe onychomycosis. .Int J Dermatol35::587. ,1996. .8854163"},{"key":"R58","series-title":"Dermatology","first-page":"47","volume":"199","year":"1999","unstructured":"Wang DL, Wang AP, Li RY, et al: Therapeutic efficacy and safety of one-week intermittent therapy with itraconazole for onychomycosis in a Chinese patient population. .Dermatology199::47. ,1999. .10449957"},{"key":"R59","series-title":"J Eur Acad Dermatol Venereol","first-page":"109","volume":"11","year":"1998","unstructured":"Ramos-e-Silva M, Marques SA, Gontijo B, et al: Efficacy and safety of itraconazole pulse therapy: Brazilian multicentric study on toenail onychomycosis caused by dermatophytes. .J Eur Acad Dermatol Venereol11::109. ,1998. .9784035"},{"key":"R60","series-title":"JAPMA","first-page":"127","volume":"91","year":"2001","unstructured":"Pollak R, Billstein SA: Efficacy of terbinafine for toenail onychomycosis: a multicenter trial of various treatment durations. .JAPMA91::127. ,2001. ."},{"key":"R61","series-title":"Mycoses","first-page":"521","volume":"41","year":"1998","unstructured":"Haneke E, Abeck D, Ring J: Safety and efficacy of intermittent therapy with itraconazole in finger- and toenail onychomycosis: a multicentre trial. .Mycoses41::521. ,1998. .9919897"},{"key":"R62","series-title":"Mycopathologia","first-page":"149","volume":"56","year":"1975","unstructured":"Mahgoub ES: Clinical trial with clotrimazole cream (Bay b 5097) in dermatophytosis and onychomycosis. .Mycopathologia56::149. ,1975. .128698"},{"key":"R63","series-title":"S Afr Med J","first-page":"57","volume":"62","year":"1982","unstructured":"Bentley-Phillips B: The treatment of onychomycosis with miconazole tincture. .S Afr Med J62::57. ,1982. .6211785"},{"key":"R64","series-title":"Dermatology","first-page":"185","volume":"200","year":"2000","unstructured":"Pierard GE, Pierard-Franchimont C, Arrese JE: The boosted oral antifungal treatment for onychomycosis beyond the regular itraconazole pulse dosing regimen. .Dermatology200::185. ,2000. .10773718"},{"key":"R65","series-title":"Mycoses","first-page":"63","volume":"41","year":"1998","unstructured":"Torok I, Simon G, Dobozy A, et al: Long-term post-treatment follow-up of onychomycosis treated with terbinafine: a multicentre trial. .Mycoses41::63. ,1998. .9610137"},{"key":"R66","series-title":"Mycoses","first-page":"93","volume":"34","year":"1991","unstructured":"Wu YC, Chuan MT, Lu YC: Efficacy of ciclopiroxolamine 1% cream in onychomycosis and tinea pedis. .Mycoses34::93. ,1991. .1833642"},{"key":"R67","series-title":"Mycoses","first-page":"167","volume":"33","year":"1990","unstructured":"Hardjoko FS, Widyanto S, Singgih I, et al: Treatment of onychomycosis with a bifonazoleurea combination. .Mycoses33::167. ,1990. .2146498"},{"key":"R68","series-title":"Int J Dermatol","first-page":"586","volume":"30","year":"1991","unstructured":"Arenas R, Fernandez G, Dominguez L: Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent. .Int J Dermatol30::586. ,1991. .1657803"},{"key":"R69","series-title":"Mycoses","first-page":"135","volume":"38","year":"1995","unstructured":"Matsumoto T, Tanuma H, Kaneko S, et al: Clinical and pharmacokinetic investigations of oral terbinafine in patients with tinea unguium. .Mycoses38::135. ,1995. .7477090"},{"key":"R70","series-title":"Int J Dermatol","first-page":"861","volume":"39","year":"2000","unstructured":"Smith EB, Stein LF, Fivenson DP, et al: Clinical trial: the safety of terbinafine in patients over the age of 60 years: a multicenter trial in onychomycosis of the feet. .Int J Dermatol39::861. ,2000. .11123452"},{"key":"R71","series-title":"Br J Dermatol","first-page":"753","volume":"121","year":"1989","unstructured":"Goodfield MJ, Rowell NR, Forster RA, et al: Treatment of dermatophyte infection of the finger- and toenails with terbinafine (SF 86-327, Lamisil), an orally active fungicidal agent. .Br J Dermatol121::753. ,1989. .2532927"},{"key":"R72","series-title":"Acta Derm Venereol","first-page":"137","volume":"70","year":"1990","unstructured":"Walsoe I, Stangerup M, Svejgaard E: Itraconazole in onychomycosis: open and double-blind studies. .Acta Derm Venereol70::137. ,1990. .1969198"},{"key":"R73","series-title":"Postgrad Med","first-page":"12","year":"1999","unstructured":"Kejda J: Itraconazole pulse therapy vs terbinafine continuous dosing for toenail onychomycosis. .Postgrad Med  (July):12. ,1999. ."},{"key":"R74","series-title":"J Am Acad Dermatol","first-page":"595","volume":"34","year":"1996","unstructured":"Tosti A, Piraccini BM, Stinchi C, et al: Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. .J Am Acad Dermatol34::595. ,1996. .8601647"},{"key":"R75","series-title":"J Dermatol","first-page":"259","volume":"23","year":"1996","unstructured":"Alpsoy E, Yilmaz E, Basaran E: Intermittent therapy with terbinafine for dermatophyte toe onychomycosis: a new approach. .J Dermatol23::259. ,1996. .8935341"},{"key":"R76","series-title":"Br J Dermatol","first-page":"36","volume":"126","year":"1992","unstructured":"Van der Schroeff JG, Cirkel PK, Crijns MB, et al: A randomized treatment duration-finding study of terbinafine in onychomycosis. .Br J Dermatol126::36. ,1992. .1531927"},{"key":"R77","series-title":"Acta Derm Venereol","first-page":"221","volume":"79","year":"1999","unstructured":"Degreef H, del Palacio A, Mygind S, et al: Randomized double-blind comparison of short-term itraconazole and terbinafine therapy for toenail onychomycosis. .Acta Derm Venereol79::221. ,1999. .10384922"},{"key":"R78","year":"2002","unstructured":"2002 Drug Topics Red Book: The Pharmacist\u2019s Trusted Companion for More Than a Century, Thomson Medical Economics, Montvale, NJ. ,2002. ."},{"key":"R79","year":"2003","unstructured":"Walgreens Web site. Available at: http:\/\/www.walgreens.com. Accessed February 28. ,2003. ."},{"key":"R80","series-title":"J Dermatol Treat","first-page":"93","volume":"8","year":"1997","unstructured":"Baran R, Belaich S, Beylot C, et al: Comparative multicenter double-blind study of terbinafine (250mg per day) versus griseofulvin (1g per day) in the treatment of dermatophyte onychomycosis. .J Dermatol Treat8::93. ,1997. ."},{"key":"R81","series-title":"BMJ","first-page":"1031","volume":"318","year":"1993","unstructured":"Evans EGV, Sigurgeirsson B: Double blind, randomized study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. .BMJ318::1031. ,1993. ."},{"key":"R82","series-title":"Arch Dermatol","first-page":"353","volume":"138","year":"2002","unstructured":"Sigurgeirsson B, Olafsson JH, Steinsson JB, et al: Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. .Arch Dermatol138::353. ,2002. .11902986"},{"key":"R83","series-title":"Int J Dermatol","first-page":"589","volume":"35","year":"1996","unstructured":"Jones HE, Zaias N: Double-blind, randomized comparison of itraconazole capsules and placebo in onychomycosis of toenail. .Int J Dermatol35::589. ,1996. .8854164"},{"key":"R84","year":"2003","unstructured":"Physicians\u2019 Desk Reference, p 1790, Thomson PDR, Montvale, NJ. ,2003. ."},{"key":"R85","series-title":"Acta Derm Venereol","first-page":"66","volume":"77","year":"1997","unstructured":"Svejgaard EL, Brandrup F, Kragballe K, et al: Oral terbinafine in toenail dermatophytosis: a double-blind, placebo-controlled multicenter study with 12 months\u2019 follow-up. .Acta Derm Venereol77::66. ,1997. .9059684"},{"key":"R86","year":"2003","unstructured":"Physicians\u2019 Desk Reference, p 2282, Thomson PDR, Montvale, NJ. ,2003. ."},{"key":"R87","series-title":"J Am Acad Dermatol","first-page":"485","volume":"44","year":"2001","unstructured":"Gupta AK, Lynde CW, Konnikov N: Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. .J Am Acad Dermatol44::485. ,2001. .11209119"},{"key":"R88","series-title":"Arch Dermatol","first-page":"1609","volume":"134","year":"1998","unstructured":"Bigby M: Evidence-based medicine in a nutshell. .Arch Dermatol134::1609. ,1998. .9875202"},{"key":"R89","series-title":"Arch Dermatol","first-page":"795","volume":"139","year":"2003","unstructured":"Bigby M, Williams H: Appraising systematic reviews and meta-analyses. .Arch Dermatol139::795. ,2003. .12810513"},{"key":"R90","series-title":"Br J Dermatol","first-page":"118","volume":"147","year":"2002","unstructured":"Haugh M, Helou S, Boissel JP, et al: Terbinafine in fungal infections of the nails: a meta-analysis of randomized clinical trials. .Br J Dermatol147::118. ,2002. .12100193"}],"container-title":["Journal of the American Podiatric Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/japmaonline.org\/view\/journals\/apms\/96\/1\/0960038.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/japma\/article-pdf\/96\/1\/38\/1417143\/0960038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/japmaonline.org\/downloadpdf\/journals\/apms\/96\/1\/0960038.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/japmaonline.org\/downloadpdf\/journals\/apms\/96\/1\/0960038.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:46:15Z","timestamp":1783428375000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1930-8264\/96\/1\/38"}},"subtitle":["A Practitioner\u2019s Perspective"],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":90,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.7547\/0960038","relation":{},"ISSN":["8750-7315","1930-8264"],"issn-type":[{"value":"8750-7315","type":"print"},{"value":"1930-8264","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}